iShares Core S&P Small-Cap

Latest iShares Core S&P Small-Cap News and Updates

  • uploads/// Population over  US
    Company & Industry Overviews

    Why Structural Hurdles Could Thwart US Economic Progress

    The American economy is facing major structural issues that have the potential to thwart economic progress. The most important hurdle facing the US economy is an aging population.

    By Rick Rieder
  • uploads///last
    Earnings Report

    How Can Century Aluminum Manage the Current Downtrend?

    Fortunately for Century Aluminum, its leverage ratios are currently much lower than other companies in this space. CENX has $123 million in cash that should help it manage its operations over the next few quarters

    By Mohit Oberoi, CFA
  • uploads///Net DEBT
    Materials

    A Look at Flotek Industries’ Debt Position in 2Q17

    In 2Q17, Flotek Industries’ (FTK) total debt fell ~34% compared to 2Q16.

    By Alex Chamberlin
  • uploads///part
    Macroeconomic Analysis

    Is the Steel Industry Gaining Strength?

    This year, steel companies have had a mixed performance on Wall Street. However, there are signs of a revival in the steel industry.

    By Mohit Oberoi, CFA
  • uploads///MDXG EPS Trend
    Company & Industry Overviews

    Behind MiMedx Group’s Recent Financial Performance

    In 3Q17, MiMedx Group’s (MDXG) net sales rose to $84.6 million, compared with $64.4 million in 3Q16—a 31% YoY (year-over-year) rise.

    By Kenneth Smith
  • uploads///Nektar Analysts Reco
    Company & Industry Overviews

    Analysts’ Ratings for Nektar Therapeutics in January 2018

    San Francisco–based biopharmaceutical company Nektar Therapeutics (NKTR) develops drug candidates that make use of its advanced polymer conjugate technology platforms.

    By Kenneth Smith
  • uploads///Part
    Company & Industry Overviews

    Analysts’ Recommendations for PetMed Express and Peers in 2017

    Of the five analysts covering PetMed Express (PETS) in October 2017, two gave it “strong buy” ratings, two gave it “hold” ratings, and one gave it a “sell” rating. Its target price was $43.75.

    By Kenneth Smith
  • uploads///Broker Recommendations
    Materials

    Wall Street’s Forecast for Flotek Industries before Its 3Q17 Earnings

    On October 16, 2017, all analysts tracking Flotek Industries rated it as a “buy” or some equivalent.

    By Alex Chamberlin
  • uploads///Graph
    Company & Industry Overviews

    Ligand Pharmaceuticals Projects Higher Average Royalty Rate for Promacta

    Ligand Pharmaceuticals (LGND) receives royalties from Novartis on Promacta’s sales according to a tiered annual payment structure.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Analysts’ Recommendations for Ligand Pharmaceuticals and Peers in 2017

    In 2Q17, Ligand Pharmaceuticals (LGND) reported revenues of ~$28.0 million, representing year-over-year growth of ~43.4%. LGND received ~$14.2 million in royalties, a year-over-year rise of 45.7%.

    By Margaret Patrick
  • uploads///IV
    Materials

    Flotek Industries’ Stock Price Forecast on August 10

    Flotek stock will likely close between $6.42 and $5.50 in the next seven days. Flotek’s stock price was $5.96 on August 10, 2017.

    By Alex Chamberlin
  • uploads///Stock Price and outlook
    Materials

    What Could Drive Flotek Industries’ Growth?

    Flotek Industries’ (FTK) management expressed optimism about improving pricing for FTK’s complex nano-Fluid (or CnF) products despite higher raw material costs.

    By Alex Chamberlin
  • uploads///IV
    Miscellaneous

    What’s Flotek Industries’ Stock Price Forecast on July 3?

    On July 3, 2017, Flotek’s (FTK) implied volatility was ~58%. Since its 1Q17 earnings were announced on May 3, 2017, FTK’s implied volatility has remained unchanged.

    By Alex Chamberlin
  • uploads///part__q
    Earnings Report

    Why Did H.B. Fuller’s Construction Products Revenue Fall?

    H.B. Fuller’s (FUL) Construction Products segment reported revenue of $64.4 million in 3Q16, which is 12.6% of the company’s total revenue.

    By Peter Neil
  • uploads///annual revenue projections
    Company & Industry Overviews

    What Is Ligand Pharmaceuticals’s Expected Revenue Growth in 2016?

    Ligand Pharmaceuticals (LGND) is a high-growth company with a comparatively low-risk business model. It earns most of its revenue from royalty and license fees.

    By Jillian Dabney
  • uploads/// US GDP
    Company & Industry Overviews

    Why Warren Buffett Strongly Believes in the American Dream

    Buffett said that it has been a terrible mistake to bet against America, not only for the past 240 years but even now. He believes that America’s emphasis on innovation and strength in commerce will continue to provide strong gains for its people.

    By Peter Barnes
  • uploads///C PIC
    Company & Industry Overviews

    Investing in Education Realty Trust: A Must-Know Company Overview

    Education Realty Trust is a self-managed and self-administered equity REIT. The main objective of the company is to develop, acquire, own, and manage student housing properties.

    By Peter Barnes
  • uploads///part  shipments
    Earnings Report

    Why Century Aluminum’s Shipments Could Fall More

    Century Aluminum’s (CENX) consolidated shipments in 3Q15 were down 1% as compared to 2Q15. In 4Q14, CENX had acquired Alcoa’s stake in the Mt. Holly smelter.

    By Mohit Oberoi, CFA
  • uploads///part
    Earnings Report

    AK Steel’s 2Q15 Earnings and Outlook

    AK Steel (AKS) reported its 2Q15 earnings on July 28. The company’s share price rose significantly after it released its second quarter results.

    By Mohit Oberoi, CFA
  • uploads///World steel production
    Macroeconomic Analysis

    World Steel Production Declined in April

    According to data released on May 25 by the WSA, world crude steel production totaled 135 million tons in April. This is a decline of 1.7% YoY.

    By Anuradha Garg
  • © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.